NO163131C - Analogifremgangsmåte for fremstilling av terapeutisk aktive pyridinderivater. - Google Patents

Analogifremgangsmåte for fremstilling av terapeutisk aktive pyridinderivater.

Info

Publication number
NO163131C
NO163131C NO853226A NO853226A NO163131C NO 163131 C NO163131 C NO 163131C NO 853226 A NO853226 A NO 853226A NO 853226 A NO853226 A NO 853226A NO 163131 C NO163131 C NO 163131C
Authority
NO
Norway
Prior art keywords
preparation
therapeutically active
pyridine derivatives
analogous process
active pyridine
Prior art date
Application number
NO853226A
Other languages
English (en)
Norwegian (no)
Other versions
NO853226L (no
NO163131B (no
Inventor
Akira Nohara
Yoshitaka Maki
Original Assignee
Takeda Chemical Industries Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=15916456&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO163131(C) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Takeda Chemical Industries Ltd filed Critical Takeda Chemical Industries Ltd
Publication of NO853226L publication Critical patent/NO853226L/no
Publication of NO163131B publication Critical patent/NO163131B/no
Publication of NO163131C publication Critical patent/NO163131C/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/89—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members with hetero atoms directly attached to the ring nitrogen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62—Oxygen or sulfur atoms
    • C07D213/63—One oxygen atom
    • C07D213/68—One oxygen atom attached in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
NO853226A 1984-08-16 1985-08-15 Analogifremgangsmåte for fremstilling av terapeutisk aktive pyridinderivater. NO163131C (no)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP59171069A JPS6150978A (ja) 1984-08-16 1984-08-16 ピリジン誘導体およびその製造法

Publications (3)

Publication Number Publication Date
NO853226L NO853226L (no) 1986-02-17
NO163131B NO163131B (no) 1990-01-02
NO163131C true NO163131C (no) 1994-10-24

Family

ID=15916456

Family Applications (2)

Application Number Title Priority Date Filing Date
NO853226A NO163131C (no) 1984-08-16 1985-08-15 Analogifremgangsmåte for fremstilling av terapeutisk aktive pyridinderivater.
NO1995002C NO1995002I1 (no) 1984-08-16 1995-03-31 Lansoprazol/ 2-[3-metyl-4-(2,2,2-trifluoretoksy)-pyrid-2-yl]metylsylfinylbenzimidazol

Family Applications After (1)

Application Number Title Priority Date Filing Date
NO1995002C NO1995002I1 (no) 1984-08-16 1995-03-31 Lansoprazol/ 2-[3-metyl-4-(2,2,2-trifluoretoksy)-pyrid-2-yl]metylsylfinylbenzimidazol

Country Status (23)

Country Link
US (2) US4628098A (fr)
EP (1) EP0174726B1 (fr)
JP (1) JPS6150978A (fr)
KR (1) KR920002128B1 (fr)
AU (1) AU570130B2 (fr)
BG (1) BG60415B2 (fr)
CA (1) CA1255314A (fr)
DE (3) DE3569736D1 (fr)
DK (1) DK171340B1 (fr)
ES (1) ES8607288A1 (fr)
GE (1) GEP19960313B (fr)
GR (1) GR851981B (fr)
HK (1) HK4792A (fr)
HU (1) HU195210B (fr)
IE (1) IE58363B1 (fr)
MX (1) MX9203043A (fr)
NL (1) NL930109I2 (fr)
NO (2) NO163131C (fr)
PH (1) PH20946A (fr)
SG (1) SG103291G (fr)
SU (1) SU1507211A3 (fr)
UA (1) UA7140A1 (fr)
ZA (1) ZA856117B (fr)

Families Citing this family (243)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0174717B1 (fr) 1984-07-06 1992-01-22 FISONS plc Benzimidazoles, et leur préparation, formulation et application comme inhibiteur de sécrétion d'acide gastrique
CA1276017C (fr) * 1986-02-13 1990-11-06 Takeda Chemical Industries, Ltd. Derives de sulfenamide, et leur production
US6749864B2 (en) 1986-02-13 2004-06-15 Takeda Chemical Industries, Ltd. Stabilized pharmaceutical composition
CA1327010C (fr) * 1986-02-13 1994-02-15 Tadashi Makino Compositions pharmaceutiques contenant un compose anti-ulcereux de type benzimidazole et sa production
US5433959A (en) 1986-02-13 1995-07-18 Takeda Chemical Industries, Ltd. Stabilized pharmaceutical composition
DK171989B1 (da) * 1987-08-04 1997-09-08 Takeda Chemical Industries Ltd Fremgangsmåde til fremstilling af 2-(2-pyridylmethylsulfinyl)-benzimidazoler
WO1989011479A1 (fr) * 1988-05-25 1989-11-30 Byk Gulden Lomberg Chemische Fabrik Gmbh Nouveaux composes fluores d'alkoxyde
US5223515A (en) * 1988-08-18 1993-06-29 Takeda Chemical Industries, Ltd. Injectable solution containing a pyridyl methylsulfinylbenzimidazole
JP2536173B2 (ja) * 1988-08-18 1996-09-18 武田薬品工業株式会社 注射剤
AT391693B (de) * 1988-11-15 1990-11-12 Cl Pharma Verfahren zur herstellung von 3-5-dimethyl-4methoxypyridinderivaten sowie neues zwischenprodukt hierfuer
IE64199B1 (en) * 1988-12-22 1995-07-12 Haessle Ab Compound with gastric acid inhibitory effect and process for its preparation
SE8804628D0 (sv) 1988-12-22 1988-12-22 Ab Haessle New compounds
SE8804629D0 (sv) * 1988-12-22 1988-12-22 Ab Haessle New therapeutically active compounds
DK0382489T3 (da) * 1989-02-10 1995-01-16 Takeda Chemical Industries Ltd Monoklonalt anti-humant papillomvirusantistof, hybridomcelle, der producerer dette, samt fremgangsmåde til fremstilling deraf
US5049674A (en) * 1989-12-20 1991-09-17 Aktiebolaget Hassle Therapeutically active fluoro substituted benzimidazoles
US4965269A (en) * 1989-12-20 1990-10-23 Ab Hassle Therapeutically active chloro substituted benzimidazoles
US5274099A (en) * 1989-12-20 1993-12-28 Aktiebolaget Hassle Therapeutically active fluoro substituted benzimidazoles
CA2053527C (fr) 1990-10-17 2002-03-12 Takashi Sohda Derives de la pyridine, leur production et leur utilisation
TW209174B (fr) 1991-04-19 1993-07-11 Takeda Pharm Industry Co Ltd
NZ244301A (en) * 1991-09-20 1994-08-26 Merck & Co Inc Preparation of 2-pyridylmethylsulphinylbenzimidazole and pyridoimidazole derivatives from the corresponding sulphenyl compounds
ES2036948B1 (es) * 1991-11-21 1994-09-01 Genesis Para La Investigacion Procedimiento de obtencion de compuestos derivados de piridina.
BR9306702A (pt) * 1992-07-08 1998-12-08 Monsanto Co Benzimidazóis para aliviar úlceras estomacais em suínos
EP0652751B1 (fr) * 1992-07-28 1996-10-23 Astra Aktiebolag Injection et trousse d'injection contenant de l'omeprazole et ses analogues
CA2156258A1 (fr) * 1993-02-17 1994-09-01 Bernhard Kohl Derives de substitution d'heteroarylalkylthiopyridines pour le controle des bacteries helicobacter
ES2060541B1 (es) * 1993-02-26 1995-11-16 Vinas Lab Nuevo procedimiento para la sintesis de un derivado de 2-(2-piridilmetilsufinil) bencimidazol, y nuevos productos intermedios obtenidos con el mismo.
ES2063705B1 (es) * 1993-06-14 1995-07-16 S A L V A T Lab Sa Intermedio para la sintesis de lansoprazol y su procedimiento de obtencion.
DK0706523T3 (da) * 1993-06-29 2001-06-18 Byk Gulden Lomberg Chem Fab Substituerede arylthioalkylthiopyridiner
TW280770B (fr) * 1993-10-15 1996-07-11 Takeda Pharm Industry Co Ltd
US5502195A (en) * 1993-11-04 1996-03-26 Slemon; Clarke Sulfoxide-carboxylate intermediates of omeprazole and lansoprazole
US5374730A (en) * 1993-11-04 1994-12-20 Torcan Chemical Ltd. Preparation of omeprazole and lansoprazole
CN1048980C (zh) * 1994-03-29 2000-02-02 广东汕头鮀滨化学药业总公司 一种新的吡啶衍生物及其制备方法和应用
CA2192206A1 (fr) * 1994-06-10 1995-12-21 Bernhard Kohl Thiopyridines utilisees pour lutter contre les bacteries helicobacter
SE9402431D0 (sv) * 1994-07-08 1994-07-08 Astra Ab New tablet formulation
SE504459C2 (sv) * 1994-07-15 1997-02-17 Astra Ab Förfarande för framställning av substituerade sulfoxider
GB9423968D0 (en) * 1994-11-28 1995-01-11 Astra Ab Resolution
SE9500422D0 (sv) * 1995-02-06 1995-02-06 Astra Ab New oral pharmaceutical dosage forms
SE9500478D0 (sv) * 1995-02-09 1995-02-09 Astra Ab New pharmaceutical formulation and process
US5708017A (en) * 1995-04-04 1998-01-13 Merck & Co., Inc. Stable, ready-to-use pharmaceutical paste composition containing proton pump inhibitors
HRP960232A2 (en) * 1995-07-03 1998-02-28 Astra Ab A process for the optical purification of compounds
US5824339A (en) * 1995-09-08 1998-10-20 Takeda Chemical Industries, Ltd Effervescent composition and its production
CN1093855C (zh) * 1995-09-21 2002-11-06 帕斯医药股份有限公司 新的含有对酸不稳定的奥美拉唑的组合物及其制备方法
SE521100C2 (sv) * 1995-12-15 2003-09-30 Astra Ab Förfarande för framställning av en bensimidazolförening
US5840737A (en) 1996-01-04 1998-11-24 The Curators Of The University Of Missouri Omeprazole solution and method for using same
US6489346B1 (en) * 1996-01-04 2002-12-03 The Curators Of The University Of Missouri Substituted benzimidazole dosage forms and method of using same
US6645988B2 (en) * 1996-01-04 2003-11-11 Curators Of The University Of Missouri Substituted benzimidazole dosage forms and method of using same
US6699885B2 (en) * 1996-01-04 2004-03-02 The Curators Of The University Of Missouri Substituted benzimidazole dosage forms and methods of using same
SE9600070D0 (sv) 1996-01-08 1996-01-08 Astra Ab New oral pharmaceutical dosage forms
US8071128B2 (en) 1996-06-14 2011-12-06 Kyowa Hakko Kirin Co., Ltd. Intrabuccally rapidly disintegrating tablet and a production method of the tablets
US6380222B2 (en) 1996-10-11 2002-04-30 Astrazeneca Ab Use of an H+, K+-atpase inhibitor in the treatment of nasal polyps
TW385306B (en) * 1996-11-14 2000-03-21 Takeda Chemical Industries Ltd Method for producing crystals of benzimidazole derivatives
US6051570A (en) * 1997-05-30 2000-04-18 Dr. Reddy's Research Foundation Benzimidazole derivatives as antiulcer agents, process for their preparation and pharmaceutical compositions containing them
US6303644B1 (en) 1997-07-25 2001-10-16 Byk Gulden Lomberg Chemische Fabrik Gmbh Proton pump inhibitor in therapeutic combination with antibacterial substances
SE9704870D0 (sv) 1997-12-22 1997-12-22 Astra Ab New pharmaceutical formulation I
KR100554924B1 (ko) 1998-05-18 2006-03-03 다케다 야쿠힌 고교 가부시키가이샤 구강내 붕괴 정제
ZA9810765B (en) * 1998-05-28 1999-08-06 Ranbaxy Lab Ltd Stable oral pharmaceutical composition containing a substituted pyridylsulfinyl benzimidazole.
IE990506A1 (en) * 1998-06-26 2000-11-15 Russinsky Ltd Pyridine Building Blocks
SI20019A (sl) * 1998-07-13 2000-02-29 LEK, tovarna farmacevtskih in kemi�nih izdelkov, d.d. Izboljšan postopek sinteze 5-metoksi -2-/(4-metoksi-3,5-dimetil-2-piridil)metil/ sulfinil-1H-benzimidazola
ES2182554T3 (es) * 1998-07-22 2003-03-01 Sepracor Inc Composiciones farmaceuticas que comprenden hiddroxilansoprazol y uso de las mismas.
US6093734A (en) * 1998-08-10 2000-07-25 Partnership Of Michael E. Garst, George Sachs, And Jai Moo Shin Prodrugs of proton pump inhibitors
TR200100431T2 (tr) 1998-08-10 2001-06-21 Partnership Of Michael E. Garst, George Sachs & Jai Moo Proton pompalama önleyici ilaçlar
WO2000009092A1 (fr) 1998-08-12 2000-02-24 Byk Gulden Lomberg Chemische Fabrik Gmbh Forme d'administration orale des pyridin-2-ylmethylsulfinyl-1h-benzimidazoles -
DE19843413C1 (de) * 1998-08-18 2000-03-30 Byk Gulden Lomberg Chem Fab Neue Salzform von Pantoprazol
JP3926936B2 (ja) * 1998-11-16 2007-06-06 エーザイ・アール・アンド・ディー・マネジメント株式会社 スルホキシド誘導体・アセトン錯体およびその製造法
US20040224989A1 (en) * 1999-01-29 2004-11-11 Barberich Timothy J. S-lansoprazole compositions and methods
US6852739B1 (en) * 1999-02-26 2005-02-08 Nitromed Inc. Methods using proton pump inhibitors and nitric oxide donors
TWI243672B (en) 1999-06-01 2005-11-21 Astrazeneca Ab New use of compounds as antibacterial agents
JP4980527B2 (ja) 1999-06-07 2012-07-18 ニコメッド ゲゼルシャフト ミット ベシュレンクテル ハフツング 酸に不安定な活性化合物を含有する新規の製剤および投与形
TWI289557B (en) 1999-06-17 2007-11-11 Takeda Chemical Industries Ltd A crystal of a hydrate of (R)-2-[[[3-methyl-4-(2,2,2-trifluoroethoxy)-2-pyridyl]methyl]sulfinyl]-1H-benzimidazole
US6245913B1 (en) 1999-06-30 2001-06-12 Wockhardt Europe Limited Synthetic procedure for 5-methoxy-2-[(4-methoxy-3,5-dimethyl-2-pyridinyl)-methylthio]-IH-benzimidazole hydrochloride and its conversion to omeprazole
AU5705700A (en) * 1999-06-30 2001-01-22 Takeda Chemical Industries Ltd. Crystals of benzimidazole compounds
US6316020B1 (en) 1999-08-26 2001-11-13 Robert R. Whittle Pharmaceutical formulations
US6369087B1 (en) 1999-08-26 2002-04-09 Robert R. Whittle Alkoxy substituted benzimidazole compounds, pharmaceutical preparations containing the same, and methods of using the same
US6312712B1 (en) 1999-08-26 2001-11-06 Robert R. Whittle Method of improving bioavailability
US6268385B1 (en) 1999-08-26 2001-07-31 Robert R. Whittle Dry blend pharmaceutical formulations
US6262086B1 (en) 1999-08-26 2001-07-17 Robert R. Whittle Pharmaceutical unit dosage form
US6312723B1 (en) 1999-08-26 2001-11-06 Robert R. Whittle Pharmaceutical unit dosage form
US6262085B1 (en) 1999-08-26 2001-07-17 Robert R. Whittle Alkoxy substituted Benzimidazole compounds, pharmaceutical preparations containing the same, and methods of using the same
US6326384B1 (en) 1999-08-26 2001-12-04 Robert R. Whittle Dry blend pharmaceutical unit dosage form
US6780880B1 (en) 1999-08-26 2004-08-24 Robert R. Whittle FT-Raman spectroscopic measurement
US6228400B1 (en) 1999-09-28 2001-05-08 Carlsbad Technology, Inc. Orally administered pharmaceutical formulations of benzimidazole derivatives and the method of preparing the same
KR100359256B1 (ko) * 1999-10-06 2002-11-04 한미약품공업 주식회사 란소프라졸의 개선된 제조방법
SE9903831D0 (sv) 1999-10-22 1999-10-22 Astra Ab Formulation of substituted benzimidazoles
US20060034937A1 (en) * 1999-11-23 2006-02-16 Mahesh Patel Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
US20030180352A1 (en) * 1999-11-23 2003-09-25 Patel Mahesh V. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
US7732404B2 (en) 1999-12-30 2010-06-08 Dexcel Ltd Pro-nanodispersion for the delivery of cyclosporin
SE0000774D0 (sv) 2000-03-08 2000-03-08 Astrazeneca Ab New formulation
ES2171116B1 (es) * 2000-04-14 2003-08-01 Esteve Quimica Sa Procedimiento para la obtencion de derivados de (((piridil sustituido)metil)tio)bencimidazol.
EP1293507B1 (fr) * 2000-05-15 2007-11-28 Takeda Pharmaceutical Company Limited Procede de production d'un cristal
CA2417311C (fr) 2000-08-04 2012-07-10 Takeda Chemical Industries, Ltd. Sels cristallins de metal alcalin et de lansoprazole et methode de production et utilisation connexes
US6544556B1 (en) 2000-09-11 2003-04-08 Andrx Corporation Pharmaceutical formulations containing a non-steroidal antiinflammatory drug and a proton pump inhibitor
AU2001296908A1 (en) * 2000-09-29 2002-04-08 Geneva Pharmaceuticals, Inc. Proton pump inhibitor formulation
KR20100002278A (ko) * 2000-12-01 2010-01-06 다케다 야쿠힌 고교 가부시키가이샤 (ｒ)- 또는 (ｓ)-란소프라졸의 결정
AU2002221939A1 (en) 2000-12-07 2002-06-18 Byk Gulden Lomberg Chemische Fabrik G.M.B.H. Rapidly disintegrating tablet comprising an acid-labile active ingredient
JP4241041B2 (ja) 2000-12-07 2009-03-18 ニコメッド ゲゼルシャフト ミット ベシュレンクテル ハフツング 酸分解性活性成分を含有するペースト形の医薬品製造物
AU2002234545A1 (en) 2000-12-07 2002-06-18 Byk Gulden Lomberg Chemische Fabrik G.M.B.H. Pharmaceutical preparation in the form of a suspension comprising an acid-labileactive ingredient
KR100430575B1 (ko) * 2001-02-21 2004-05-10 주식회사 씨트리 란소프라졸 및 그 중간체의 제조방법
US6645946B1 (en) 2001-03-27 2003-11-11 Pro-Pharmaceuticals, Inc. Delivery of a therapeutic agent in a formulation for reduced toxicity
SE0101379D0 (sv) 2001-04-18 2001-04-18 Diabact Ab Komposition som hämmar utsöndring av magsyra
US8206741B2 (en) 2001-06-01 2012-06-26 Pozen Inc. Pharmaceutical compositions for the coordinated delivery of NSAIDs
SE0102993D0 (sv) 2001-09-07 2001-09-07 Astrazeneca Ab New self emulsifying drug delivery system
JP4020076B2 (ja) 2001-09-18 2007-12-12 ゼリア新薬工業株式会社 ベンズイミダゾール誘導体
US20040248941A1 (en) * 2001-09-25 2004-12-09 Keiji Kamiyama Benzimidazone compound, process for producing the same, and use thereof
US9358214B2 (en) 2001-10-04 2016-06-07 Adare Pharmaceuticals, Inc. Timed, sustained release systems for propranolol
US8101209B2 (en) 2001-10-09 2012-01-24 Flamel Technologies Microparticulate oral galenical form for the delayed and controlled release of pharmaceutical active principles
US8105626B2 (en) 2001-10-17 2012-01-31 Takeda Pharmaceutical Company Limited Granules containing acid-unstable chemical in large amount
SE0104295D0 (sv) * 2001-12-18 2001-12-18 Astrazeneca Ab New process
RU2215739C1 (ru) * 2002-04-03 2003-11-10 Федеральное государственное унитарное предприятие "Государственный научный центр "Научно-исследовательский институт органических полупродуктов и красителей" Способ получения 5-метокси-2-(4-метокси-3,5-диметил-2-пиридилметилтио)бензимидазола
DE60323474D1 (de) 2002-04-09 2008-10-23 Flamel Tech Sa Orale pharmazeutische formulierung in form einer wässrigen suspension von mikrokapseln zur modifizierten freisetzung von amoxicillin
MXPA04009968A (es) 2002-04-09 2004-12-13 Flamel Tech Sa Formulacion farmaceutica oral bajo forma de suspension acuosa de microcapsulas que permiten la liberacion modificada de principio (s) activo (s).
US20030228363A1 (en) * 2002-06-07 2003-12-11 Patel Mahendra R. Stabilized pharmaceutical compositons containing benzimidazole compounds
KR100873419B1 (ko) * 2002-06-18 2008-12-11 페어차일드코리아반도체 주식회사 높은 항복 전압, 낮은 온 저항 및 작은 스위칭 손실을갖는 전력용 반도체 소자
RU2292342C2 (ru) * 2002-07-19 2007-01-27 Уинстон Фармасьютикалс ЛЛС. Производные бензимидазола и их применение в качестве пролекарств ингибиторов протонного насоса
TW200410955A (en) 2002-07-29 2004-07-01 Altana Pharma Ag Novel salt of (S)-PANTOPRAZOLE
AU2003254282A1 (en) * 2002-08-01 2004-02-23 Nitromed, Inc. Nitrosated proton pump inhibitors, compositions and methods of use
ATE375338T1 (de) * 2002-08-21 2007-10-15 Teva Pharma Verfahren zur aufreinigung von lanzoprazol
PL373433A1 (en) 2002-08-30 2005-08-22 Altana Pharma Ag The use of the combination of ciclesonide and antihistamines for the treatment of allergic rhinitis
MY148805A (en) 2002-10-16 2013-05-31 Takeda Pharmaceutical Controlled release preparation
SE0203065D0 (sv) 2002-10-16 2002-10-16 Diabact Ab Gastric acid secretion inhibiting composition
EP1552833B1 (fr) 2002-10-16 2016-12-28 Takeda Pharmaceutical Company Limited Procédé de préparation d'un iosmère optiquement actif du lansoprazole
EP1743893A1 (fr) 2002-11-18 2007-01-17 Teva Pharmaceutical Industries Ltd. Lansoprazole stable contenant plus de 500 parties par million, jusqu'à environ 3000 parties par million d'eau et plus de 200 parties par million, jusqu'à environ 5000 parties par million d'alcool
EP1465890B1 (fr) * 2002-11-18 2007-04-04 Teva Pharmaceutical Industries Ltd. Lansoprazole stable contenant plus de 500 parties par million, jusqu'a environ 3000 parties par million d'eau et plus de 200 parties par million, jusqu'a environ 5000 parties par million d'alcool
DE10254167A1 (de) 2002-11-20 2004-06-09 Icon Genetics Ag Verfahren zur Kontrolle von zellulären Prozessen in Pflanzen
AU2003293749B2 (en) 2002-12-06 2009-12-24 Takeda Gmbh Process for preparing (S)-pantoprazole
ES2397380T3 (es) 2002-12-06 2013-03-06 Takeda Gmbh Procedimiento para preparar compuestos activos ópticamente puros
US7507829B2 (en) * 2002-12-19 2009-03-24 Teva Pharmaceuticals Industries, Ltd Solid states of pantoprazole sodium, processes for preparing them and processes for preparing known pantoprazole sodium hydrates
US8367111B2 (en) 2002-12-31 2013-02-05 Aptalis Pharmatech, Inc. Extended release dosage forms of propranolol hydrochloride
US7678816B2 (en) * 2003-02-05 2010-03-16 Teva Pharmaceutical Industries Ltd. Method of stabilizing lansoprazole
US20050220870A1 (en) * 2003-02-20 2005-10-06 Bonnie Hepburn Novel formulation, omeprazole antacid complex-immediate release for rapid and sustained suppression of gastric acid
WO2004080439A1 (fr) * 2003-03-12 2004-09-23 Takeda Pharmaceutical Company Limited Composition de medicament comportant un principe actif adhere en concentration elevee a un noyau spherique
ES2245277T1 (es) * 2003-03-12 2006-01-01 Teva Pharmaceutical Industries Limited Solidos cristalinos y amorfos de pantoprazol y procedimientos para su preparacion.
US7608625B2 (en) * 2003-03-13 2009-10-27 Eisai R & D Management Co., Ltd. Method for treating bruxism and bruxism-related diseases
WO2004093875A1 (fr) * 2003-04-22 2004-11-04 Dr. Reddy's Laboratories Limited Formulations pharmaceutiques orales à base de principes actifs labiles en milieu acide et de dérivés glucides hydrosolubles, utilisation de ces formulations, et procédé de fabrication approprié
PE20050150A1 (es) 2003-05-08 2005-03-22 Altana Pharma Ag Una forma de dosificacion que contiene (s)-pantoprazol como ingrediente activo
CL2004000983A1 (es) 2003-05-08 2005-03-04 Altana Pharma Ag Composicion farmaceutica oral en forma de tableta que comprende a pantoprazol magnetico dihidratado, en donde la forma de tableta esta compuesto por un nucleo, una capa intermedia y una capa exterior; y uso de la composicion farmaceutica en ulceras y
MXPA05013316A (es) * 2003-06-10 2006-03-17 Teva Pharma Proceso para preparar bencimidazoles 2[-(piridinil)metil]sulfinil-sustituidos y derivados clorados novedosos de pantoprazol.
EP2112920B1 (fr) * 2003-06-26 2018-07-25 Intellipharmaceutics Corp. Capsules contenant un inhibiteur de la pompe a protons comprenant des unites secondaires differemment structurees permettant une liberation retardee de l'ingredient actif
JP2007521314A (ja) * 2003-07-15 2007-08-02 アラーガン、インコーポレイテッド プロトンポンプ阻害薬の異性体純粋なプロドラッグを製造するための方法
US8993599B2 (en) 2003-07-18 2015-03-31 Santarus, Inc. Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
JP2007504261A (ja) * 2003-09-03 2007-03-01 エイジーアイ・セラピューティクス・リサーチ・リミテッド プロトンポンプ阻害剤製剤、並びに当該製剤を製造及び使用する方法関連出願の表示
TWI372066B (en) 2003-10-01 2012-09-11 Wyeth Corp Pantoprazole multiparticulate formulations
WO2005039640A1 (fr) * 2003-10-03 2005-05-06 Allergan Inc. Compositions contenant des peptides en trefle et/ou des mucoadhesifs et des promedicaments d'un inhibiteur de pompe a proton
US20050075371A1 (en) * 2003-10-03 2005-04-07 Allergan, Inc. Methods and compositions for the oral administration of prodrugs of proton pump inhibitors
JP2007522217A (ja) * 2004-02-10 2007-08-09 サンタラス インコーポレイティッド プロトンポンプ阻害剤、緩衝剤および非ステロイド系抗炎症薬の組み合わせ
GB0403165D0 (en) * 2004-02-12 2004-03-17 Ct Novel uses for proton pump inhibitors
AU2005216862A1 (en) * 2004-02-18 2005-09-09 Allergan, Inc. Compositions comprising prodrugs of proton pump inhibitors
AU2005216863A1 (en) * 2004-02-18 2005-09-09 Allergan, Inc. Methods and compositions for the intravenous administration of compounds related to proton pump inhibitors
US20050214372A1 (en) * 2004-03-03 2005-09-29 Simona Di Capua Stable pharmaceutical composition comprising an acid labile drug
US20050239845A1 (en) * 2004-04-16 2005-10-27 Santarus, Inc. Combination of proton pump inhibitor, buffering agent, and prokinetic agent
US20070219236A1 (en) * 2004-04-28 2007-09-20 Atlanta Pharma Ag Dialkoxy-Imidazopyridines Derivatives
US8815916B2 (en) 2004-05-25 2014-08-26 Santarus, Inc. Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
US8906940B2 (en) 2004-05-25 2014-12-09 Santarus, Inc. Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
EP1768668A2 (fr) 2004-06-16 2007-04-04 Tap Pharmaceutical Products, Inc. Forme posologique a doses ppi multiples
US8394409B2 (en) 2004-07-01 2013-03-12 Intellipharmaceutics Corp. Controlled extended drug release technology
US20060024362A1 (en) * 2004-07-29 2006-02-02 Pawan Seth Composition comprising a benzimidazole and process for its manufacture
US10624858B2 (en) 2004-08-23 2020-04-21 Intellipharmaceutics Corp Controlled release composition using transition coating, and method of preparing same
EP1790647B1 (fr) 2004-09-13 2013-05-08 Takeda Pharmaceutical Company Limited Procede destines a produire un compose oxyde
US8747895B2 (en) 2004-09-13 2014-06-10 Aptalis Pharmatech, Inc. Orally disintegrating tablets of atomoxetine
US9884014B2 (en) 2004-10-12 2018-02-06 Adare Pharmaceuticals, Inc. Taste-masked pharmaceutical compositions
AU2005299490C1 (en) 2004-10-21 2012-01-19 Adare Pharmaceuticals, Inc. Taste-masked pharmaceutical compositions with gastrosoluble pore-formers
US20060105038A1 (en) * 2004-11-12 2006-05-18 Eurand Pharmaceuticals Limited Taste-masked pharmaceutical compositions prepared by coacervation
KR20070109985A (ko) 2004-11-22 2007-11-15 아나디스 리미티드 생물활성 조성물
EP1681056A1 (fr) 2005-01-14 2006-07-19 Krka Tovarna Zdravil, D.D., Novo Mesto Procédé de préparation du lansoprazole
EP2275088B2 (fr) 2005-02-25 2018-09-26 Takeda Pharmaceutical Company Limited Procédé de fabrication de granulés
KR100771659B1 (ko) 2005-03-23 2007-10-30 주식회사 카이로제닉스 판토프라졸 및 그 중간체의 제조방법
US9161918B2 (en) 2005-05-02 2015-10-20 Adare Pharmaceuticals, Inc. Timed, pulsatile release systems
US7981908B2 (en) 2005-05-11 2011-07-19 Vecta, Ltd. Compositions and methods for inhibiting gastric acid secretion
US7803817B2 (en) 2005-05-11 2010-09-28 Vecta, Ltd. Composition and methods for inhibiting gastric acid secretion
WO2006132217A1 (fr) 2005-06-07 2006-12-14 Takeda Pharmaceutical Company Limited Cristal d'un sel d'un compose de benzimidazole
EP1903039A4 (fr) * 2005-06-13 2010-09-22 Takeda Pharmaceutical Produit d injection
US7601737B2 (en) 2005-07-26 2009-10-13 Nycomed Gmbh Isotopically substituted proton pump inhibitors
US7598273B2 (en) * 2005-10-06 2009-10-06 Auspex Pharmaceuticals, Inc Inhibitors of the gastric H+, K+-ATPase with enhanced therapeutic properties
GB0525710D0 (en) * 2005-12-17 2006-01-25 Pliva Hrvatska D O O An improved process for preparing of substituted 2-benzimidazolesulfoxide compounds
US10064828B1 (en) 2005-12-23 2018-09-04 Intellipharmaceutics Corp. Pulsed extended-pulsed and extended-pulsed pulsed drug delivery systems
JP5053865B2 (ja) 2005-12-28 2012-10-24 武田薬品工業株式会社 口腔内崩壊性固形製剤の製造法
WO2007074909A1 (fr) 2005-12-28 2007-07-05 Takeda Pharmaceutical Company Limited Preparation solide a liberation controlee
PL2003130T3 (pl) * 2006-03-10 2012-04-30 Link Genomics Inc Nowa pochodna pirydyny o aktywności przeciwko helicobacter pylori
WO2007112581A1 (fr) 2006-04-03 2007-10-11 Isa Odidi Dispositif d'administration à libération commandée comprenant un enrobage organosol
US10960077B2 (en) 2006-05-12 2021-03-30 Intellipharmaceutics Corp. Abuse and alcohol resistant drug composition
WO2007138606A2 (fr) * 2006-06-01 2007-12-06 Dexcel Pharma Technologies Ltd. Formulation pharmaceutique comprenant des unités multiples
US7863330B2 (en) * 2006-06-14 2011-01-04 Rottapharm S.P.A. Deloxiglumide and proton pump inhibitor combination in the treatment of gastrointestinal disorders
US9233092B2 (en) 2006-07-25 2016-01-12 Vecta, Ltd. Compositions and methods for inhibiting gastric acid secretion using derivatives of small dicarboxylic acids in combination with PPI
WO2008036201A1 (fr) * 2006-09-19 2008-03-27 Alevium Pharmaceuticals, Inc. Promédicaments d'inhibiteurs de pompes à protons comprenant le groupe fonctionnel 1h-imidazo[4,5-b] pyridine
WO2008035189A1 (fr) * 2006-09-22 2008-03-27 Orchid Chemicals & Pharmaceuticals Limited Procédé de purification du lansoprazole
CA2665226C (fr) 2006-10-05 2014-05-13 Santarus, Inc. Nouvelles formulations pour une liberation immediate d'inhibiteurs de pompe a protons et procedes d'utilisation de ces formulations
AU2007317561A1 (en) 2006-10-27 2008-05-15 The Curators Of The University Of Missouri Compositions comprising at least one acid labile proton pump inhibiting agents, optionally other pharmaceutically active agents and methods of using same
NZ598728A (en) 2006-12-22 2013-09-27 Ironwood Pharmaceuticals Inc Compositions comprising bile acid sequestrants for treating esophageal disorders
JP5366558B2 (ja) 2006-12-28 2013-12-11 武田薬品工業株式会社 口腔内崩壊性固形製剤
WO2008087665A2 (fr) * 2007-01-18 2008-07-24 Matrix Laboratories Ltd Procédé de préparation de lansoprazole
US20080194307A1 (en) * 2007-02-13 2008-08-14 Jeff Sanger Sports-based game of chance
TW200840574A (en) * 2007-04-02 2008-10-16 Univ Nat Taiwan The pharmaceutical component for treating hearing loss disease
EP2181106A1 (fr) * 2007-07-17 2010-05-05 Ranbaxy Laboratories Limited Procédé de préparation de pantoprazole sodique.
CN102014638A (zh) 2007-10-12 2011-04-13 武田制药北美公司 与食物摄入无关的治疗胃肠病症的方法
EP2222663A1 (fr) * 2007-12-18 2010-09-01 Watson Pharma Private Limited Procédé de préparation de r-lansoprazole amorphe stable
EP2573082A1 (fr) 2007-12-31 2013-03-27 Takeda Pharmaceutical Company Limited Formes dissoutes cristallines de (R) -2-[[[3-méthyl-4- (2, 2, 2-trifluoroéthoxy) -2-pyridinyl]méthyl]sulfinyl]-1h-benzimidazole
CN101980700A (zh) 2008-02-20 2011-02-23 密苏里大学董事会 包含奥美拉唑和兰索拉唑以及缓冲剂的组合的组合物及其使用方法
US20090227633A1 (en) * 2008-03-04 2009-09-10 Bassam Damaj Methods to inhibit tumor cell growth by using proton pump inhibitors
AU2009224247B2 (en) 2008-03-10 2013-12-12 Takeda Pharmaceutical Company Limited Crystal of benzimidazole compound
US20090263475A1 (en) * 2008-04-21 2009-10-22 Nagaraju Manne Dexlansoprazole compositions
BRPI0912478A2 (pt) 2008-05-14 2016-02-10 Watson Pharma Private Ltd sal de r-(+)-lansoprazol alquilamina, processo para preparar um sal de r-(+)-lansoprazol alquilamina estável e forma de dosagem farmacêutica
EA201100313A1 (ru) 2008-09-09 2011-10-31 Астразенека Аб Способ доставки фармацевтической композиции пациенту, нуждающемуся в этом
US20100113527A1 (en) * 2008-09-30 2010-05-06 Teva Pharmaceutical Industries Ltd. Crystalline forms of dexlansoprazole
US20100093747A1 (en) * 2008-10-10 2010-04-15 Erica Brook Goodhew Method of inducing negative chemotaxis
US11304960B2 (en) 2009-01-08 2022-04-19 Chandrashekar Giliyar Steroidal compositions
WO2010122583A2 (fr) 2009-04-24 2010-10-28 Rubicon Research Private Limited Compositions pharmaceutiques orales comprenant des substances labiles en milieu acide
WO2010134099A1 (fr) 2009-05-21 2010-11-25 Cadila Healthcare Limited Procédé de préparation dans un récipient unique d'oméprazole
WO2011004387A2 (fr) 2009-06-18 2011-01-13 Matrix Laboratories Ltd Procédé de préparation de formes polymorphes du dexlansoprazole
CA2764963C (fr) 2009-06-25 2016-11-01 Astrazeneca Ab Procede pour le traitement d'un patient a risque de developer un ulcere associe a nsaid
KR101765357B1 (ko) 2009-12-02 2017-08-04 아데어 파마수티컬스 에스.알.엘. 펙소페나딘 마이크로캡슐 및 그것을 함유하는 조성물
WO2011080500A2 (fr) 2009-12-29 2011-07-07 Orexo Ab Nouvelle forme pharmaceutique destinée au traitement de troubles liés à l'acide gastrique
WO2011080501A2 (fr) 2009-12-29 2011-07-07 Orexo Ab Nouvelle forme pharmaceutique destinée au traitement de troubles liés à l'acide gastrique
WO2011080502A2 (fr) 2009-12-29 2011-07-07 Orexo Ab Nouvelle forme pharmaceutique destinée au traitement de troubles liés à l'acide gastrique
AR079862A1 (es) * 2010-01-08 2012-02-22 Eurand Inc Composicion de topiramato con sabor enmascarado, un comprimido desintegrable oralmente que comprende la misma y metodo de preparacion
US20110189271A1 (en) * 2010-02-02 2011-08-04 Vishal Lad Pharmaceutical formulations of acid-labile drugs
WO2011138797A2 (fr) 2010-05-04 2011-11-10 Cadila Healthcare Limited Composition pharmaceutique de lansoprazole à action différée se désintégrant par la voie buccale
US20130216617A1 (en) 2010-06-29 2013-08-22 Cadila Healthcare Limited Pharmaceutical compositions of (r)-lansoprazole
US20130156720A1 (en) 2010-08-27 2013-06-20 Ironwood Pharmaceuticals, Inc. Compositions and methods for treating or preventing metabolic syndrome and related diseases and disorders
US9034858B2 (en) 2010-11-30 2015-05-19 Lipocine Inc. High-strength testosterone undecanoate compositions
US9358241B2 (en) 2010-11-30 2016-06-07 Lipocine Inc. High-strength testosterone undecanoate compositions
US20180153904A1 (en) 2010-11-30 2018-06-07 Lipocine Inc. High-strength testosterone undecanoate compositions
WO2012074110A1 (fr) 2010-12-03 2012-06-07 武田薬品工業株式会社 Comprimé à désintégration orale
US20120148675A1 (en) 2010-12-10 2012-06-14 Basawaraj Chickmath Testosterone undecanoate compositions
US20130273157A1 (en) 2010-12-27 2013-10-17 Takeda Pharmaceutical Company Limited Orally disintegrating tablet
US9233103B2 (en) 2011-03-25 2016-01-12 Takeda Pharmaceuticals U.S.A., Inc. Methods for treating heartburn, gastric bleeding or hemorrhage in patients receiving clopidogrel therapy
CA2857457C (fr) 2011-11-30 2018-05-01 Takeda Pharmaceutical Company Limited Comprime enrobe a sec
EP2601947A1 (fr) 2011-12-05 2013-06-12 Abo Bakr Mohammed Ali Al-Mehdar Combinaison à dose fixe pour le traitement de maladies associées à Hélicobacter pylori
KR20140113667A (ko) 2011-12-16 2014-09-24 아토픽스 테라퓨릭스 리미티드 호산구성 식도염의 치료를 위한 ｃｒｔｈ2 길항제 및 양성자 펌프 저해제의 조합
BR112014016085A8 (pt) 2011-12-28 2017-07-04 Pozen Inc composições aprimoradas e métodos para distribuição de omeprazol mais ácido acetilsalicílico
WO2013108068A1 (fr) 2012-01-21 2013-07-25 Jubilant Life Sciences Limited Procédé de préparation de 2-pyridinylméthylsulfinylbenzimidazoles, leurs analogues et énantiomères optiquement actifs
CA2898362C (fr) 2013-01-15 2020-09-01 Ironwood Pharmaceuticals, Inc. Forme posologique orale a liberation prolongee a retention gastrique d'un agent sequestrant d'acide biliaire
SG11201509439SA (en) 2013-05-21 2015-12-30 Takeda Pharmaceutical Orally disintegrable tablet
US9457011B2 (en) 2014-02-25 2016-10-04 Muslim D. Shahid Compositions and methods for the treatment of acid-related gastrointestinal disorders containing a dithiolane compound and a gastric acid secretion inhibitor
US20170246187A1 (en) 2014-08-28 2017-08-31 Lipocine Inc. (17-ß)-3-OXOANDROST-4-EN-17-YL TRIDECANOATE COMPOSITIONS AND METHODS OF THEIR PREPARATION AND USE
US9498485B2 (en) 2014-08-28 2016-11-22 Lipocine Inc. Bioavailable solid state (17-β)-hydroxy-4-androsten-3-one esters
US20180015118A1 (en) 2015-02-03 2018-01-18 Ironwood Pharmaceuticals, Inc. Methods of treating upper gastrointestinal disorders in ppi refractory gerd
US20170042806A1 (en) 2015-04-29 2017-02-16 Dexcel Pharma Technologies Ltd. Orally disintegrating compositions
US20160361322A1 (en) 2015-06-15 2016-12-15 Lipocine Inc. Composition and method for oral delivery of androgen prodrugs
US10736855B2 (en) 2016-02-25 2020-08-11 Dexcel Pharma Technologies Ltd. Compositions comprising proton pump inhibitors
US10076494B2 (en) 2016-06-16 2018-09-18 Dexcel Pharma Technologies Ltd. Stable orally disintegrating pharmaceutical compositions
US20180147215A1 (en) 2016-11-28 2018-05-31 Lipocine Inc. Oral testosterone undecanoate therapy
CN107365300B (zh) * 2017-07-26 2019-08-02 桂林华信制药有限公司 一种有效去除兰索拉唑粗品中杂质的方法
US12150945B2 (en) 2018-07-20 2024-11-26 Lipocine Inc. Liver disease
CN114163419A (zh) * 2021-12-24 2022-03-11 辰欣药业股份有限公司 一种兰索拉唑的制备方法
WO2024075017A1 (fr) 2022-10-04 2024-04-11 Zabirnyk Arsenii Inhibition de calcification de valve aortique

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE416649B (sv) * 1974-05-16 1981-01-26 Haessle Ab Forfarande for framstellning av foreningar som paverkar magsyrasekretionen
SE7804231L (sv) * 1978-04-14 1979-10-15 Haessle Ab Magsyrasekretionsmedel
US4359465A (en) * 1980-07-28 1982-11-16 The Upjohn Company Methods for treating gastrointestinal inflammation
IL66340A (en) * 1981-08-13 1986-08-31 Haessle Ab Pharmaceutical compositions comprising pyridylmethyl-thiobenzimidazole derivatives,certain such novel derivatives and their preparation
US4472409A (en) * 1981-11-05 1984-09-18 Byk Gulden Lomberg Chemische Fabrik Gesellschaft Mit Beschrankter Haftung 2-Pyridylmethyl thio(sulfinyl)benzimidazoles with gastric acid secretion inhibiting effects
SE8300736D0 (sv) * 1983-02-11 1983-02-11 Haessle Ab Novel pharmacologically active compounds
HU195220B (en) * 1983-05-03 1988-04-28 Byk Gulden Lomberg Chem Fqb Process for production of new fluor-alkoxi-benzimidasole-derivatives and medical compositions containig them
US4575554A (en) * 1983-12-05 1986-03-11 The Upjohn Company Substituted 2-pyridylmethylthio- and sulfinyl-benzimidazoles as gastric antisecretory agents
IL75400A (en) * 1984-06-16 1988-10-31 Byk Gulden Lomberg Chem Fab Dialkoxypyridine methyl(sulfinyl or sulfonyl)benzimidazoles,processes for the preparation thereof and pharmaceutical compositions containing the same
GB8417171D0 (en) * 1984-07-05 1984-08-08 Beecham Group Plc Compounds
SE8404065D0 (sv) * 1984-08-10 1984-08-10 Haessle Ab Novel biologically active compounds

Also Published As

Publication number Publication date
PH20946A (en) 1987-06-10
US4689333A (en) 1987-08-25
US4628098A (en) 1986-12-09
GR851981B (fr) 1985-12-16
IE58363B1 (en) 1993-09-08
JPH0244473B2 (fr) 1990-10-04
JPS6150978A (ja) 1986-03-13
DK171340B1 (da) 1996-09-16
DK356485A (da) 1986-02-17
DK356485D0 (da) 1985-08-06
UA7140A1 (uk) 1995-06-30
DE19975020I2 (de) 2009-08-06
KR870002125A (ko) 1987-03-30
GEP19960313B (en) 1996-06-24
SU1507211A3 (ru) 1989-09-07
NO853226L (no) 1986-02-17
NO163131B (no) 1990-01-02
AU570130B2 (en) 1988-03-03
NO1995002I1 (no) 1995-03-31
BG60415B2 (bg) 1995-02-28
NL930109I1 (nl) 1993-10-18
NL930109I2 (nl) 1997-02-03
MX9203043A (es) 1992-07-01
CA1255314A (fr) 1989-06-06
HK4792A (en) 1992-01-17
DE19975017I2 (de) 2009-08-06
HU195210B (en) 1988-04-28
DE3569736D1 (en) 1989-06-01
KR920002128B1 (ko) 1992-03-12
ES546152A0 (es) 1986-05-16
EP0174726B1 (fr) 1989-04-26
SG103291G (en) 1993-02-19
HUT39444A (en) 1986-09-29
ZA856117B (en) 1986-04-30
EP0174726A1 (fr) 1986-03-19
IE851976L (en) 1986-02-16
AU4589585A (en) 1986-02-20
ES8607288A1 (es) 1986-05-16

Similar Documents

Publication Publication Date Title
FI883739A7 (fi) Menetelmä terapeuttisesti aktiivisten fenoksi-indaanimetyyliamiinijohdannaisten valmistamiseksi
NO177387C (no) Analogifremgangsmåte for fremstilling av terapeutisk aktive imidazo-kondenserte, 6-leddede, heterocykliske forbindelser
FI96861C (fi) Menetelmä terapeuttisesti aktiivisten substituoitujen indolyylipyrrolijohdannaisten valmistamiseksi
NO159016C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive fenetanolaminderivater.
FI875660L (fi) Menetelmä terapeuttisesti käyttökelpoisten 5-fenyyli-2-pyrimidinonijohdannaisten valmistamiseksi
NO178619C (no) Analogifremgangsmåte for fremstilling av terapeutisk aktive di-t-butylfenoler
FI875024A7 (fi) Menetelmä terapeuttisesti käyttökelpoisten 1-alkyyli-6-halogeenitetrahydronaftaleenijohdannaisten valmistamiseksi
FI873205A0 (fi) Menetelmä terapeuttisesti aktiivisten bentsimidatsolijohdannaisten valmistamiseksi
NO853293L (no) Fremgangsmaate for fremstilling av terapeutisk aktive heterocykliske derivater.
NO173442C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive pyrimidinderivater
FI850654A0 (fi) Menetelmä terapeuttisesti käyttökelpoisten pleuromutilinijohdannaisten valmistamiseksi
NO176713C (no) Analogifremgangsmåte for fremstilling av terapeutisk aktive 4-aminopyridinderivater
NO176275C (no) Analogifremgangsmåte for fremstilling av terapeutisk aktive pyridazinonderivater
NO864110D0 (no) Fremgangsmaate for fremstilling av terapeutisk virksomme benzimidazolderivater.
NO173334C (no) Analogifremgangsm}te for fremstilling av terapeutisk aktive alkylaminoalkylenderivater 2H-1-benzopyraner
NO174959C (no) Analogifremgangsmåte for fremstilling av terapeutisk aktive N-aminobutyl-N-fenyl-arylamidderivater
FI861903A7 (fi) Menetelmä terapeuttisesti aktiivisten 2-substituoitujen 1-naftolijohdannaisten valmistamiseksi
FI884553A7 (fi) Analogiamenetelmä terapeuttisesti käyttökelpoisten 9-aminotetrahydroakridiinijohdannaisten valmistamiseksi
NO159930C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive indeno-pyridazinon-derivater.
FI871087A7 (fi) Menetelmä terapeuttisesti aktiivisten 1,2,3,4-tetrahydro-3-karbamoyyli-2-tiokso/okso-5-pyrimidiinikarboksyylihappojohdannaisten valmistamiseksi
FI93215C (fi) Menetelmä terapeuttisesti käyttökelpoisten aminoalkoksifenyylijohdannaisten valmistamiseksi
NO163775C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive isoindolinyl-alkyl-piperaziner.
FI882002L (fi) Menetelmä terapeuttisesti aktiivisten fenyylipiperidiinijohdannaisten valmistamiseksi
FI880190A0 (fi) Menetelmä valmistaa terapeuttisesti vaikuttavia tetrahydrofuraanijohdoksia
NO163330C (no) Analogifremgangsmaate ved fremstilling av terapeutisk aktive isokinolinderivater.

Legal Events

Date Code Title Description
MK1K Patent expired